HC Wainwright initiated coverage on shares of Mural Oncology (NASDAQ:MURA – Free Report) in a report published on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $18.00 price objective on the stock.
A number of other analysts also recently weighed in on MURA. Rodman & Renshaw started coverage on shares of Mural Oncology in a research report on Friday, June 28th. They issued a “buy” rating and a $15.00 price target on the stock. Raymond James assumed coverage on shares of Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock.
Mural Oncology Stock Performance
Mural Oncology (NASDAQ:MURA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. Equities analysts forecast that Mural Oncology will post -7.47 EPS for the current year.
Institutional Investors Weigh In On Mural Oncology
Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in shares of Mural Oncology during the second quarter worth $998,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mural Oncology during the second quarter worth $84,000. Armistice Capital LLC bought a new stake in shares of Mural Oncology during the second quarter worth $5,300,000. Primecap Management Co. CA bought a new stake in shares of Mural Oncology during the second quarter worth $740,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Mural Oncology during the second quarter worth $70,000. Institutional investors own 80.21% of the company’s stock.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Further Reading
- Five stocks we like better than Mural Oncology
- Dividend Payout Ratio Calculator
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What Does a Stock Split Mean?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.